NO20052912L - Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil - Google Patents
Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinilInfo
- Publication number
- NO20052912L NO20052912L NO20052912A NO20052912A NO20052912L NO 20052912 L NO20052912 L NO 20052912L NO 20052912 A NO20052912 A NO 20052912A NO 20052912 A NO20052912 A NO 20052912A NO 20052912 L NO20052912 L NO 20052912L
- Authority
- NO
- Norway
- Prior art keywords
- modafinil
- optical enantiomers
- crystalline forms
- preparing crystalline
- crystalline
- Prior art date
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001165 modafinil Drugs 0.000 title abstract 4
- 230000003287 optical effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/06—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Oppfinnelsen vedrører en fremgangsmåte for fremstilling av krystallinske former av de optiske enantiomerer av modafinil, omfattende de følgende trinn: i) oppløsning av en av de optiske enantiomerer av modafinil i et annet løsningsmiddel enn etanol, ii) modafinilenantiomeren krystalliseres, iii) den krystallinske form av modafinilenantiomeren oppnådd på denne måte utvinnes. Oppfinnelsen vedrører o gså en fremgangsmåte for fremstilling av de optiske enantiomerer av modafinil.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216412A FR2849029B1 (fr) | 2002-12-20 | 2002-12-20 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
PCT/FR2003/003799 WO2004060858A1 (fr) | 2002-12-20 | 2003-12-18 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20052912D0 NO20052912D0 (no) | 2005-06-15 |
NO20052912L true NO20052912L (no) | 2005-07-19 |
NO335724B1 NO335724B1 (no) | 2015-02-02 |
Family
ID=32406320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052912A NO335724B1 (no) | 2002-12-20 | 2005-06-15 | Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse |
Country Status (29)
Country | Link |
---|---|
US (10) | US7132570B2 (no) |
EP (6) | EP2343275B1 (no) |
JP (2) | JP4719471B2 (no) |
KR (1) | KR101050565B1 (no) |
CN (5) | CN101654423A (no) |
AR (1) | AR042546A1 (no) |
AU (2) | AU2003299349C1 (no) |
CA (2) | CA2724305A1 (no) |
CL (2) | CL2007002450A1 (no) |
CY (1) | CY1114291T1 (no) |
DK (1) | DK2343275T3 (no) |
EA (1) | EA009592B1 (no) |
EG (1) | EG24849A (no) |
ES (3) | ES2575018T3 (no) |
FR (1) | FR2849029B1 (no) |
HK (2) | HK1192222A1 (no) |
IL (1) | IL169205A (no) |
IS (1) | IS7947A (no) |
MX (1) | MXPA05006525A (no) |
MY (1) | MY142926A (no) |
NO (1) | NO335724B1 (no) |
NZ (2) | NZ571235A (no) |
PL (1) | PL377196A1 (no) |
PT (1) | PT2343275E (no) |
SI (1) | SI2343275T1 (no) |
TW (1) | TWI344952B (no) |
UA (1) | UA100964C2 (no) |
WO (1) | WO2004060858A1 (no) |
ZA (1) | ZA200504805B (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
JP4906233B2 (ja) | 2002-03-01 | 2012-03-28 | ユニバーシティー オブ サウス フロリダ | 少なくとも1種の有効薬剤成分を含有する多構成要素固相 |
JP2006500377A (ja) | 2002-06-21 | 2006-01-05 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 改善された溶解性を有する医薬組成物 |
FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
AU2003217437A1 (en) * | 2003-03-17 | 2004-10-11 | Hetero Drugs Limited | Novel crystalline forms of lamotrigine |
CA2519117C (en) * | 2003-03-17 | 2010-03-02 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
JP4842819B2 (ja) * | 2003-09-04 | 2011-12-21 | セフアロン・インコーポレーテツド | モダフィニル組成物 |
US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
EP1516869A1 (en) | 2003-09-19 | 2005-03-23 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
CA2556106A1 (en) * | 2004-02-06 | 2005-08-25 | Cephalon, Inc. | Modafinil compositions |
US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
EP2292213A1 (en) * | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
US20060086667A1 (en) * | 2004-09-13 | 2006-04-27 | Cephalon, Inc., U.S. Corporation | Methods for the separation of enantiomeric sulfinylacetamides |
EP1702915A1 (en) * | 2005-03-14 | 2006-09-20 | Cephalon France | Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation |
CA2614777C (en) * | 2005-07-21 | 2012-04-17 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
US20070293702A1 (en) * | 2006-02-21 | 2007-12-20 | Viviana Braude | Novel crystalline forms of armodafinil and preparation thereof |
EP2159219A3 (en) | 2006-03-01 | 2010-12-15 | Teva Pharmaceutical Industries Ltd. | An improved process for the preparation of armodafinil |
KR20090031618A (ko) * | 2006-07-12 | 2009-03-26 | 엘란 코포레이션, 피엘씨 | 나노입자형 모다피닐 제제 |
CA2660565C (en) * | 2006-08-14 | 2012-10-09 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
US20080214862A1 (en) * | 2006-12-06 | 2008-09-04 | Ben-Zion Dolitzky | Processes for preparing armodafinil intermediate |
WO2008077127A2 (en) * | 2006-12-19 | 2008-06-26 | Lavin Thomas N | Use of modafinil to treat restless leg syndrome |
CA2688430A1 (en) * | 2007-06-04 | 2008-12-11 | Generics [Uk] Limited | Novel process |
WO2009024863A2 (en) * | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
US7960586B2 (en) * | 2007-08-16 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Purification of armodafinil |
US20090082462A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched armodafinil |
US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
WO2009090663A1 (en) * | 2008-01-15 | 2009-07-23 | Lupin Limited | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof |
US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
US20100036164A1 (en) * | 2008-08-06 | 2010-02-11 | Srinivas Areveli | Preparation of armodafinil form i |
EP2292306B1 (en) * | 2009-09-02 | 2013-05-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device |
EP2501674A2 (en) * | 2009-11-19 | 2012-09-26 | Ranbaxy Laboratories Limited | Processes for preparation of polymorphic forms of lacosamide |
KR20120101588A (ko) * | 2010-01-07 | 2012-09-13 | 비버스 인크. | 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료 |
US9267159B2 (en) | 2010-12-08 | 2016-02-23 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
JP6116847B2 (ja) * | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation | シクロデキストリンとの混合体を含有する錠剤 |
US10466776B2 (en) * | 2014-06-24 | 2019-11-05 | Paypal, Inc. | Surfacing related content based on user interaction with currently presented content |
US10609267B2 (en) * | 2014-07-23 | 2020-03-31 | Orcam Technologies Ltd. | Systems and methods for analyzing advertisement effectiveness using wearable camera systems |
US20170304034A1 (en) * | 2014-11-27 | 2017-10-26 | Gc Corporation | Surface treatment agent for wax pattern and method of manufacturing dental prosthesis |
WO2017064723A1 (en) * | 2015-10-12 | 2017-04-20 | Natco Pharma Ltd | An improved process for the preparation of armodafinil |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1905990A (en) | 1931-01-02 | 1933-04-25 | Hoffmann La Roche | Disubstituted carbamic acid esters of phenols containing a basic constituent |
GB1197809A (en) | 1968-02-13 | 1970-07-08 | Inst Noguchi | Method for Continuous Optical Resolution of Organic Racemates. |
GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
FR2597864B1 (fr) | 1986-04-28 | 1990-11-16 | Lafon Labor | Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique |
FR2626881B1 (fr) | 1988-02-10 | 1990-07-27 | Lafon Labor | 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique |
FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
FR2671349B1 (fr) | 1991-01-09 | 1993-04-23 | Lafon Labor | Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant. |
FR2710337B1 (fr) * | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
CN1249932A (zh) | 1999-09-29 | 2000-04-12 | 付俊昌 | 一种莫达芬尼及其光学对映体l及d异构体的新用途 |
CA2396079A1 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
US20010036640A1 (en) | 2000-04-25 | 2001-11-01 | D'amico Kevin L. | System and methods for the high throughput screening of polymorphs |
US6670358B2 (en) | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
DE10025756C2 (de) * | 2000-05-25 | 2003-02-20 | Cognis Deutschland Gmbh | Lösungsvermittler |
AU2001283008A1 (en) * | 2000-07-27 | 2002-02-13 | Teva Pharmaceutical Industries Ltd. | Crystalline and pure modafinil, and process of preparing the same |
US6835307B2 (en) * | 2000-08-04 | 2004-12-28 | Battelle Memorial Institute | Thermal water treatment |
US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
WO2002041834A2 (en) | 2000-11-03 | 2002-05-30 | Teva Pharmaceutical Industries, Ltd. | Atorvastatin hemi-calcium form vii |
MXPA03010705A (es) * | 2001-05-25 | 2004-05-27 | Cephalon Inc | Formulaciones farmaceuticas solidas que comprenden modafinil. |
JP2005502861A (ja) | 2001-08-10 | 2005-01-27 | サイミックス テクノロジーズ, インコーポレイテッド | 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム |
ATE329254T1 (de) | 2002-01-15 | 2006-06-15 | Avantium Int Bv | Verfahren zur durchführung einer leistungsbeugungsanalyse |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
US6875893B2 (en) * | 2002-05-23 | 2005-04-05 | Cephalon, Inc. | Preparations of a sulfinyl acetamide |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
ATE366137T1 (de) | 2002-08-02 | 2007-07-15 | Avantium Int Bv | Vorrichtung und verfahren zur parallelen durchführung chemischer experimente, insbesondere kristallisationsexperimente |
US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
JP4903385B2 (ja) | 2002-12-06 | 2012-03-28 | パーデュー・リサーチ・ファウンデーション | 損傷した哺乳類神経組織を治療するためのピリジン類 |
FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
MXPA06002507A (es) | 2003-09-04 | 2006-06-20 | Cephalon Inc | Composiciones de modafinil. |
US7566805B2 (en) * | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
CA2556106A1 (en) | 2004-02-06 | 2005-08-25 | Cephalon, Inc. | Modafinil compositions |
CN101039921A (zh) | 2004-10-13 | 2007-09-19 | 法玛西雅厄普约翰有限责任公司 | 3-[5-氯-4-[(2,4-二氟苄基)氧基]-6-氧代嘧啶-1(6h)-基]-n-(2-羟乙基)-4-甲基苯甲酰胺的晶形 |
CA2614777C (en) * | 2005-07-21 | 2012-04-17 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
US20070293702A1 (en) * | 2006-02-21 | 2007-12-20 | Viviana Braude | Novel crystalline forms of armodafinil and preparation thereof |
EP2159219A3 (en) | 2006-03-01 | 2010-12-15 | Teva Pharmaceutical Industries Ltd. | An improved process for the preparation of armodafinil |
CA2688430A1 (en) | 2007-06-04 | 2008-12-11 | Generics [Uk] Limited | Novel process |
WO2009024863A2 (en) | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
US7960586B2 (en) | 2007-08-16 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Purification of armodafinil |
US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
EP1911739A3 (en) * | 2007-11-05 | 2008-09-17 | Dipharma Francis S.r.l. | Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate |
WO2009090663A1 (en) | 2008-01-15 | 2009-07-23 | Lupin Limited | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof |
-
2002
- 2002-12-20 FR FR0216412A patent/FR2849029B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-18 AU AU2003299349A patent/AU2003299349C1/en active Active
- 2003-12-18 SI SI200332281T patent/SI2343275T1/sl unknown
- 2003-12-18 JP JP2004564285A patent/JP4719471B2/ja not_active Expired - Fee Related
- 2003-12-18 CN CN200910152177A patent/CN101654423A/zh active Pending
- 2003-12-18 DK DK11163602.3T patent/DK2343275T3/da active
- 2003-12-18 EA EA200501016A patent/EA009592B1/ru not_active IP Right Cessation
- 2003-12-18 CA CA2724305A patent/CA2724305A1/fr not_active Abandoned
- 2003-12-18 EP EP11163602.3A patent/EP2343275B1/fr not_active Expired - Lifetime
- 2003-12-18 WO PCT/FR2003/003799 patent/WO2004060858A1/fr active Application Filing
- 2003-12-18 CA CA2510096A patent/CA2510096C/fr not_active Expired - Lifetime
- 2003-12-18 EP EP13177661.9A patent/EP2676952A3/fr not_active Withdrawn
- 2003-12-18 ES ES13177660.1T patent/ES2575018T3/es not_active Expired - Lifetime
- 2003-12-18 CN CN201610461501.9A patent/CN106065007A/zh active Pending
- 2003-12-18 EP EP13177660.1A patent/EP2679578B1/fr not_active Expired - Lifetime
- 2003-12-18 EP EP03799631.1A patent/EP1572635B1/fr not_active Expired - Lifetime
- 2003-12-18 KR KR1020057011619A patent/KR101050565B1/ko active IP Right Grant
- 2003-12-18 US US10/539,918 patent/US7132570B2/en not_active Expired - Fee Related
- 2003-12-18 EP EP13177648.6A patent/EP2679576A3/fr not_active Withdrawn
- 2003-12-18 PL PL377196A patent/PL377196A1/pl unknown
- 2003-12-18 PT PT111636023T patent/PT2343275E/pt unknown
- 2003-12-18 CN CN2010101503175A patent/CN101914044A/zh active Pending
- 2003-12-18 MX MXPA05006525A patent/MXPA05006525A/es active IP Right Grant
- 2003-12-18 ES ES03799631.1T patent/ES2627808T3/es not_active Expired - Lifetime
- 2003-12-18 UA UAA200507106A patent/UA100964C2/ru unknown
- 2003-12-18 CN CNB2003801098134A patent/CN100540533C/zh not_active Expired - Fee Related
- 2003-12-18 EP EP13177658.5A patent/EP2679577A3/fr not_active Withdrawn
- 2003-12-18 NZ NZ571235A patent/NZ571235A/en not_active IP Right Cessation
- 2003-12-18 NZ NZ540733A patent/NZ540733A/en not_active IP Right Cessation
- 2003-12-18 ES ES11163602T patent/ES2425023T3/es not_active Expired - Lifetime
- 2003-12-18 CN CN2007100017638A patent/CN101012189B/zh not_active Expired - Fee Related
- 2003-12-19 AR ARP030104730A patent/AR042546A1/es not_active Application Discontinuation
- 2003-12-22 TW TW092136443A patent/TWI344952B/zh not_active IP Right Cessation
- 2003-12-22 MY MYPI20034935A patent/MY142926A/en unknown
-
2005
- 2005-06-13 ZA ZA200504805A patent/ZA200504805B/en unknown
- 2005-06-15 NO NO20052912A patent/NO335724B1/no not_active IP Right Cessation
- 2005-06-16 IL IL169205A patent/IL169205A/en active IP Right Grant
- 2005-06-19 EG EGNA2005000326 patent/EG24849A/xx active
- 2005-07-19 IS IS7947A patent/IS7947A/is unknown
-
2006
- 2006-06-26 US US11/474,859 patent/US20060241320A1/en not_active Abandoned
-
2007
- 2007-08-22 CL CL2007002450A patent/CL2007002450A1/es unknown
-
2009
- 2009-07-22 US US12/507,610 patent/US20100048719A1/en not_active Abandoned
- 2009-07-22 US US12/507,623 patent/US20090281193A1/en not_active Abandoned
- 2009-07-22 US US12/507,631 patent/US20100048720A1/en not_active Abandoned
- 2009-07-22 US US12/507,602 patent/US20100048718A1/en not_active Abandoned
- 2009-07-22 US US12/507,584 patent/US9382200B2/en not_active Expired - Fee Related
- 2009-07-22 US US12/507,594 patent/US20090281192A1/en not_active Abandoned
-
2010
- 2010-08-20 AU AU2010212462A patent/AU2010212462A1/en not_active Abandoned
-
2011
- 2011-02-17 JP JP2011032155A patent/JP5497680B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-08 US US13/858,483 patent/US8729305B2/en not_active Expired - Fee Related
- 2013-07-08 CY CY20131100573T patent/CY1114291T1/el unknown
- 2013-08-28 US US14/012,363 patent/US8975442B2/en not_active Expired - Fee Related
-
2014
- 2014-06-13 HK HK14105599.8A patent/HK1192222A1/zh not_active IP Right Cessation
-
2016
- 2016-10-17 CL CL2016002640A patent/CL2016002640A1/es unknown
- 2016-12-01 HK HK16113750A patent/HK1225371A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052912L (no) | Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil | |
DE60316688D1 (de) | Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon | |
EA200900536A1 (ru) | Способ получения хиральных 8-(3-аминопиперидин-1-ил) ксантинов | |
NO20054614L (no) | Fremgangsmate til fremstilling av 68Ga | |
ATE417036T1 (de) | Verbessertes verfahren zur herstellung von 3- hydroxy-4-hydroxymethyl-pyrrolidin-verbindungen | |
ATE515496T1 (de) | Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure | |
EA200600485A1 (ru) | Способ получения производных 2-оксо-1-пирролидина | |
DE60326341D1 (de) | Verfahren zur herstellung von anthranilsäurederivat-hydrat | |
EA200602169A1 (ru) | Способ получения производных 2-оксо-1-пирролидина внутримолекулярным аллилированием | |
ATE445601T1 (de) | Verfahren zur herstellung von carvedilol und seinen enantiomeren | |
ATE526312T1 (de) | Verfahren zur herstellung von reinen 4- pyrrolidinophenylbenzyletherderivaten als maob- inhibitoren | |
ATE291006T1 (de) | Verfahren zur herstellung von salbutamolisomeren | |
BRPI0513881A (pt) | processo para a preparação de compostos opticamente ativos | |
ATE469149T1 (de) | Verfahren zur herstellung von cabergolin | |
WO2006034812A3 (de) | Verfahren zur herstellung von optisch aktiven 2-methylalkan-1-ols aus dem entsprechenden 2-methylalk-2-en-1-al, umfassend eine carbonylselektive reduktion, eine enantioselektive hydrierung und eine lipase-katalysierte, stereoselektive acylierung zwecks anreicherung des gewünschten enatiomers | |
DE60015563D1 (de) | Verfahren zur herstellung von benzoperhydroisoindolen | |
ATE297933T1 (de) | Ein verfahren zur herstellung von hochreinem cefpodoxim-proxetil | |
ATE549315T1 (de) | Verfahren zur herstellung von kristallinem perindopril | |
MX2007011274A (es) | Procesos y metodos para la preparacion de cis-2-hidroximetil-4-(ci tosin-1-il)-1,3-oxatiolano opticamente activas o sales aceptables farmaceuticamente del mismo. | |
DE50307171D1 (de) | Verfahren zur herstellung von 3-amidinophenylalanin-derivaten | |
ATE370950T1 (de) | Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol | |
ATE318815T1 (de) | Verfahren zur herstellung von enantiomeren von indol-2,3-dion-3-oximderivaten | |
ATE502045T1 (de) | Verfahren zur herstellung von perindoprilerbumin | |
ATE496038T1 (de) | Verfahren zur herstellung von quetiapin | |
ATE375355T1 (de) | Verfahren zur herstellung von cefpodoxim-proxetil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |